Bessemer Group’s Arcus Biosciences RCUS Stock Holding History

Bessemer Group’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Buy	629 +200	+47%	+$4.94K	﹤0.01%	2017
2026 Q1	$9K	Hold	429	–	–	﹤0.01%	2148
2025 Q4	$10K	Buy	429 +101	+31%	+$2.06K	﹤0.01%	2108
2025 Q3	$4K	Buy	328 +294	+865%	+$3.06K	﹤0.01%	2202
2025 Q2	$0	Hold	34	–	–	﹤0.01%	2602
2025 Q1	$0	Buy	+34	New	+$394	﹤0.01%	2683
2024 Q4	–	Sell	-70	Closed	-$1K	–	2647
2024 Q3	$1K	Buy	+70	New	+$1.1K	﹤0.01%	2514
2023 Q4	–	Sell	-124	Closed	-$2K	–	2260
2023 Q3	$2K	Buy	124 +61	+97%	+$1.23K	﹤0.01%	2017
2023 Q2	$1K	Buy	+63	New	+$1.2K	﹤0.01%	2210
2020 Q3	–	Sell	-47,800	Closed	-$1.18M	–	1608
2020 Q2	$1.18M	Buy	+47,800	New	+$1.29M	﹤0.01%	692

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bessemer Group's RCUS Position: Q2 2026 in Review

Bessemer Group increased its Arcus Biosciences (RCUS) stake by 47% in Q2 2026, buying an estimated $4.94K and bringing the position to 629 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Bessemer Group first reported a position in RCUS in Q2 2020 and has held it in 10 quarters since. The position peaked at $1.18M in Q2 2020. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Bessemer Group held 629 shares of Arcus Biosciences worth $19K as of Q2 2026.
Bessemer Group bought 200 Arcus Biosciences shares in Q2 2026, an estimated $4.94K.
Arcus Biosciences made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2017 holding.
Bessemer Group first reported a position in Arcus Biosciences in Q2 2020 and has held it in 10 quarters since.
Bessemer Group's Arcus Biosciences position peaked at $1.18M in Q2 2020.
232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.